GlycoMimetics (GLYC) Tops Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
GlycoMimetics (GLYC) to Present Further Analysis of Data From Phase 1/2 AML Trial of Uproleselan at ASH
November 6, 2019 10:04 AM ESTGlycoMimetics, Inc. (Nasdaq: GLYC) today announced that seven abstracts covering data from the companys research and clinical portfolio have been accepted for presentation at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 7-10, 2019 in Orlando.
Of particular note, clinical data from the Companys recent Phase 1/2 study of uproleselan, an E-selectin antagonist and the companys lead wholly owned clinical candidate, were selected for a poster presentation on Sunday, December 8 during a session on biology of AML. The presentation will feature data showing uproleselans ability... More
